Compare Abbott Laboratories (ABT) vs Avient Corporation (AVNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Avient Corporation — how do they compare? Abbott Laboratories trades at $95.4 (market cap $166.94B), while Avient Corporation trades at $35.29 (market cap $3.49B). The key difference: Abbott Laboratories is far larger — about 47.8× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| ABT | AVNT | |
|---|---|---|
Market Cap | $166.94B | $3.49B |
Sector | Health | Technology |
52-Week High | $136.62 | $43.28 |
52-Week Low | $82.57 | $27.48 |
Enterprise Value | $193.69B | $4.99B |
Dividend Yield | 2.63% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Avient Corporation (AVNT) trades at $38.89, up 4.23% today, reflecting positive momentum. The stock exhibits a bullish technical outlook with strong analyst support (12 Buy, 8 Hold, 0 Sell). Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $0.83 surpassing the $0.81 forecast. The company maintains solid fundamentals, including a P/E of 22.58 and net income margin of 4.81%, while recent news highlights innovation in non-PFAS barrier technology and new dielectric thermoplastics.
The outlook for AVNT is positive, driven by earnings outperformance, strategic product launches, and favorable analyst sentiment. Key opportunities include growth in 5G/6G materials and sustainable packaging solutions. Risks involve exposure to economic cycles impacting demand and competitive pressures in the specialty materials sector. Investors should weigh strong fundamentals against market volatility and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
